Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in Ewing sarcoma patients – associations with tumor phenotype and survival

摘要

BackgroundEwing sarcoma (ES) is driven by fusion of the EWS gene with an ETS transcription factor, most often FLI1. Neuropeptide Y (NPY) is an EWS-FLI1 transcriptional target. NPY is highly expressed in ES and exerts opposing effects, ranging from ES cell death to angiogenesis and cancer stem cell propagation. The functions of NPY are regulated by dipeptidyl peptidase IV (DPPIV), a hypoxia-inducible enzyme that cleaves the peptide and activates its growth-promoting actions. The goal of this study was to determine clinically relevant functions of NPY by identifying the associations between its concentrations and DPP activity in patients and ES phenotype.